Beam Therapeutics Inc.

NASDAQ:BEAM

Biotechnology

Healthcare
$20.94 +1.46%

+$0.48 today

Market cap
$2.17B
Beta
2.20
P/E (TTM)
-52.3
EPS (TTM)
-$0.63
52W Low $15.60High $36.44

Volume 4.21M

Average 2.11M

Income Statement

Follow revenue through to earnings.

Revenue

$139.74M

FY 2025 · Annual

+120.0% YoY

Operating Income

-$383.69M

FY 2025 · Annual

Net Income

-$79.99M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue51.84M60.92M377.71M63.52M139.74M
Cost of Revenue232.13M311.59M0367.56M22.29M
Gross Profit(180.29M)(250.67M)377.71M(304.04M)117.45M
Gross Margin-347.8%-411.5%100.0%-478.7%84.0%
Research & Development387.09M311.59M437.38M367.56M409.62M
Selling, General & Admin57.22M87.81M116.81M111.53M113.82M
Operating Expenses212.18M87.81M554.19M111.53M501.14M
Depreciation & Amortization7.45M14.15M20.01M21.93M22.29M
EBITDA(230.06M)(271.53M)(111.15M)(354.78M)(13.97M)
EBITDA Margin-443.8%-445.7%-29.4%-558.5%-10.0%
Operating Income(392.47M)(338.48M)(176.49M)(415.57M)(383.69M)
Operating Margin-757.0%-555.6%-46.7%-654.3%-274.6%
Interest Income015.3M46.68M49.09M0
Interest Expense000043.73M
Other Income / Expenses21.83M52.8M45.32M38.87M303.7M
Income Before Tax(370.64M)(285.68M)(131.16M)(376.7M)(79.99M)
Pre-Tax Margin-714.9%-468.9%-34.7%-593.1%-57.2%
Income Tax Expense03.41M1.37M39K0
Net Income(370.64M)(289.09M)(132.53M)(376.74M)(79.99M)
Net Margin-714.9%-474.5%-35.1%-593.1%-57.2%
EPS (Basic)(5.77)(4.13)(1.72)(4.58)(0.81)
EPS (Diluted)(5.77)(4.13)(1.72)(4.58)(0.81)
Weighted Avg Shares64.23M70.02M77.15M82.31M98.91M
Weighted Avg Shares (Diluted)64.23M70.02M77.15M82.31M98.91M

BEAM Earnings Waterfall · TTM

NASDAQ:BEAM · Revenue to Net Income

Key Ratios

EPS$-0.86
Gross Margin100.0%
Net Margin-6570.4%
P/E Ratio-4.1
P/S Ratio1916.6

Analysis

$156.0M of revenue converted into -$85.4M of net income for the selected period. Gross margin is 100.0% and net margin is -6570.4%, showing how much revenue survives after costs and taxes. EPS is $-0.86, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 13, 2026
8-KCurrent reportNov 3, 2026
10-QQuarterly reportNov 3, 2026
4Statement of changes in beneficial ownershipOct 16, 2026
4Statement of changes in beneficial ownershipOct 2, 2026

How much revenue does BEAM generate?

Beam Therapeutics Inc. (BEAM) reported $139.74M of revenue in fiscal 2025.

Is BEAM profitable?

Beam Therapeutics Inc. (BEAM) reported -$79.99M of net income, with a net margin of -57.2%.